Clinical

Dataset Information

0

A phase lb/ll, open label, single arm study to assess efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies


ABSTRACT: Interventions: Drug : Alpelisib: oral administration In Phase lb, 200mg and 300mg once daily will be tested. In Phase ll, the recommended phase ll dose (RP2D) in phase lb will be used. Capecitabine: oral administration, In Phase lb, 850mg, 1000mg, 1250mg twice daily will be tested. In Phase ll, the recommended phase ll dose (RP2D) in phase lb twice daily on day 1 to 14 followed by 7 days off Primary outcome(s): PFS, Progression Free Survival

DISEASE(S): Neoplasms

PROVIDER: 2513615 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| EGAS00001004930 | EGA
2021-09-09 | PXD021424 | Pride
| 2113000 | ecrin-mdr-crc
2018-08-26 | GSE82161 | GEO
2020-07-07 | GSE138723 | GEO
2020-04-07 | GSE136634 | GEO
2019-11-25 | GSE125695 | GEO
2014-11-06 | E-GEOD-48947 | biostudies-arrayexpress
| 2619853 | ecrin-mdr-crc
| 74700 | ecrin-mdr-crc